Western blot analysis from orthotopic primary ovarian tumours revealed that DEX treatment reduced the Rap1B protein level in the GFP–DEX group (Fig. 6e,f), correlated with our in vitro observation that expression of Rap1B was reduced in the presence of DEX (Fig. 3g). Here, RAP1B is linked to ovarian neoplasm.